Guardant Health Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名27/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价111.24。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。
Guardant Health Inc评分
相关信息
行业排名
27 / 208
全市场排名
86 / 4563
所属行业
医疗设备与耗材
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Guardant Health Inc亮点
亮点风险
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
公司代码GH
公司Guardant Health Inc
CEOTalasaz (Amirali)
网址https://guardanthealth.com/
常见问题
Guardant Health Inc(GH)的当前股价是多少?
Guardant Health Inc(GH)的当前股价是 108.760。
Guardant Health Inc的股票代码是什么?
Guardant Health Inc的股票代码是GH。
Guardant Health Inc股票的52周最高点是多少?
Guardant Health Inc股票的52周最高点是113.910。
Guardant Health Inc股票的52周最低点是多少?
Guardant Health Inc股票的52周最低点是34.800。
Guardant Health Inc的市值是多少?
Guardant Health Inc的市值是13.60B。
Guardant Health Inc的净利润是多少?
Guardant Health Inc的净利润为-436.37M。
现在Guardant Health Inc(GH)的股票是买入、持有还是卖出?
根据分析师评级,Guardant Health Inc(GH)的总体评级为买入,目标价格为111.237。